Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, when fused to the tat protein-transduction sequence and subsequently introduced into cells, the C2 peptides potently promoted the RhoGAP function in DLC1, leading to decreased RhoA activation and reduced tumor cell growth in soft agar and migration in response to growth factor stimulation.
|
31806702 |
2020 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A tumor suppressor DLC1: The functions and signal pathways.
|
31773748 |
2020 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 was also identified as an estrogen-induced tumor suppressor in the normal mammary gland with decreased expression in breast cancer.
|
31110002 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tripathi investigates how the tumor suppressor DLC1 is regulated by oncogenic kinases.
|
31515239 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Together, these findings indicate cooperation between the SRC, ERK1/2, and AKT kinases to reduce DLC1 Rho-GAP and tumor suppressor activities in cancer cells, which can be reactivated by the kinase inhibitors.
|
31308216 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial cell derivation.
|
31409902 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
So far, the role of the first identified member from the DLC family, DLC1, was established as a tumor suppressor in hepatocellular carcinoma.
|
30827083 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
|
29785050 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The findings indicate: 1) C3R (25 μM) has the potential to reduce RKO cell motility in vitro; 2) ingestion of lyophilized AP reduces the total number of aberrant crypt foci (ACF), ACF multiplicity, tumor cell proliferation and incidence of tumors with high grade dysplasia; 3) AP increases the gene expression of negative regulators of cell proliferation such as Dlc1 and Akt3, as well as inflammation (Ppara).
|
30194994 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor suppressor gene DLC1 is shown to induce apoptosis, suppress migration and invasion in various cancer cells.
|
29964052 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
|
30278072 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The Drosophila Crossveinless-c (Cv-c) RhoGAP is homologous to the human tumour suppressor proteins Deleted in Liver Cancer 1-3 (DLC1-3) sharing an identical arrangement of SAM, GAP and START protein domains.
|
29545526 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene frequently deleted in cancer.
|
29202196 |
2018 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor.
|
27604574 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
That binding, which interferes with the interaction of RhoA-GTP with the RhoGAP domain, reduces the hydrolysis of RhoA-GTP, the binding of other DLC1 ligands, and the colocalization of DLC1 with focal adhesions and attenuates tumor suppressor activity.
|
29114068 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A tumor suppressor Deleted in Liver Cancer 1 (DLC1) has been reported to be down-regulated or even silenced in several kinds of cancer including breast cancer.
|
27830358 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 is a RhoGAP-containing tumor suppressor that inhibits angiogenesis by repressing VEGF production in epithelial cells.
|
28408355 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This isoform is functional GAP protein and tumor suppressor and targeting of its expression results in the increase of DLC1 related cell processes: RHO activation and cell migration.
|
27614886 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 has been identified as a candidate tumor suppressor.
|
27366946 |
2016 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in liver cancer 1 (DLC1) on chromosome 8p22, is an important tumor suppressor gene originally identified to be deleted in hepatocellular carcinoma.
|
26986853 |
2016 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DLC-1 expression was not found to be associated with tumor differentiation status.
|
26514520 |
2015 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Lower expression levels of DLC1 indicated a more advanced tumor‑node‑metastasis stage, increased lymph node metastasis, deeper tumor invasion, increased tumor size and a higher rate of distant metastasis.
|
26239822 |
2015 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC-1 inhibits cell growth and invasion in human colon cancer, functioning as a tumor-suppressor gene, possibly through the regulation of the Wnt/β-catenin signaling pathway.
|
24604602 |
2014 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that DLC1 might act as a CHD-associated gene in addition to its role as a tumor suppressor in cancer.
|
24587289 |
2014 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Restoration of DLC1 expression in GBC-SD and NOZ cells significantly reduced cell proliferation, migration in vitro, and the ability of these cells to form tumors in vivo.
|
24329682 |
2014 |